Safety and immunogenicity of heterologous Ad26.ZEBOV and MVA-BN®-Filo prime-boost Ebola vaccines: 6-month follow-up of a Phase I randomized trial in healthy adults
Macaya Douoguih,
Neil Goldstein,
Stephan Bart,
Kerstin Luhn,
Wilbert Van Duijnhoven,
Carla Truyers,
Benoit Callendret
Affiliations
Macaya Douoguih
Janssen Infectious Diseases and Vaccines, Leiden, The Netherlands
Neil Goldstein
Janssen Infectious Diseases and Vaccines, Leiden, The Netherlands
Stephan Bart
Janssen Infectious Diseases and Vaccines, Leiden, The Netherlands
Kerstin Luhn
Janssen Infectious Diseases and Vaccines, Leiden, The Netherlands
Wilbert Van Duijnhoven
Janssen Infectious Diseases and Vaccines, Leiden, The Netherlands
Carla Truyers
Janssen Infectious Diseases and Vaccines, Leiden, The Netherlands
Benoit Callendret
Janssen Infectious Diseases and Vaccines, Leiden, The Netherlands
